Author: Alligator Bioscience

Posted Date:

March 10, 2026

Alligator Bioscience Strengthens Intellectual Property Protection for Bispecific Antibody Platform

Alligator Bioscience

March 10, 2026
Alligator Bioscience Comments on Henlius Dosing First Patient in Phase 2/3 Breast Cancer Study of HLX22

Alligator Bioscience

March 2, 2026
Exercise Price Determined for the Exercise of Warrants Series TO 14 in Alligator Bioscience AB

Alligator Bioscience

February 27, 2026
Alligator Bioscience AB Reports Full Year Financial Results for 2025 and for Q4 2025 and Provides a Business Update

Alligator Bioscience

February 12, 2026
Invitation to Alligator Bioscience’s Earnings Call on 12 February 2026

Alligator Bioscience

February 8, 2026
Change in Number of Shares and Votes in Alligator Bioscience AB

Alligator Bioscience

January 30, 2026